DONNA M WEBER

TitleProfessor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020 Oct 13; 4(19):4834-4837. PMID: 33027527.
      Citations:    Fields:    
    2. Hao S, Lu X, Gong Z, Bassett RL, Hu S, Konoplev SN, Tang G, Li S, Xu J, Khanlari M, Lee HC, Manasanch EE, Weber DM, Orlowski RZ, Jeffrey Medeiros L, Lin P. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Mod Pathol. 2020 Sep 09. PMID: 32908255.
      Citations:    Fields:    
    3. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):e221-e238. PMID: 32037287.
      Citations:    Fields:    
    4. Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BS. New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica. 2020 Jul; 105(7):e355-e357. PMID: 31919088.
      Citations: 2     Fields:    
    5. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 Apr; 26(4):665-671. PMID: 31881283.
      Citations: 1     Fields:    
    6. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 Jun; 26(6):1077-1083. PMID: 31786242.
      Citations:    Fields:    
    7. Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol. 2019 12; 94(12):E319-E322. PMID: 31489991.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J. 2019 10 01; 9(10):80. PMID: 31575851.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    9. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. J Natl Compr Canc Netw. 2019 10 01; 17(10):1154-1165. PMID: 31590151.
      Citations: 5     Fields:    Translation:Humans
    10. Buege MJ, Do B, Lee HC, Weber DM, Horowitz SB, Feng L, Qing Y, Shank BR. Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. Cancer Treat Res Commun. 2019; 21:100159. PMID: 31521048.
      Citations: 1     Fields:    Translation:Humans
    11. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res. 2019 11 15; 25(22):6781-6787. PMID: 31481508.
      Citations:    Fields:    Translation:HumansCells
    12. Figgins B, Primeaux B, Shank BR, Chen SE, Weber DM, Lu H. Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustine. J Oncol Pharm Pract. 2020 Jun; 26(4):982-985. PMID: 31433727.
      Citations: 1     Fields:    Translation:Humans
    13. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica. 2020 05; 105(5):e242-e245. PMID: 31413094.
      Citations: 1     Fields:    
    14. Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019 08 13; 3(15):2400-2408. PMID: 31405950.
      Citations: 4     Fields:    
    15. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol. 2019 Sep; 98(9):2233-2235. PMID: 31243571.
      Citations:    Fields:    Translation:Humans
    16. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):560-569. PMID: 31201134.
      Citations: 1     Fields:    Translation:Humans
    17. Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS. Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated? Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):e465-e469. PMID: 31133526.
      Citations:    Fields:    Translation:Humans
    18. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275. PMID: 30910541.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    19. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019 03; 94(3):E72-E74. PMID: 30548467.
      Citations:    Fields:    Translation:HumansCells
    20. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol. 2018 Dec; 5(12):e628-e640. PMID: 30501870.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    21. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 07; 54(7):1089-1093. PMID: 30446740.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    22. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5. PMID: 30300461.
      Citations:    Fields:    Translation:Humans
    23. Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma. 2019 04; 60(4):964-970. PMID: 30227761.
      Citations: 3     Fields:    Translation:Humans
    24. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2197-2203. PMID: 30016656.
      Citations: 4     Fields:    Translation:Humans
    25. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452. PMID: 30032678.
      Citations: 4     Fields:    Translation:Humans
    26. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw. 2018 01; 16(1):11-20. PMID: 29295877.
      Citations: 21     Fields:    Translation:Humans
    27. Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Weber DM, Orlowski RZ. Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget. 2017 Sep 26; 8(43):73723-73732. PMID: 29088739.
      Citations: 3     Fields:    
    28. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma. 2018 02; 59(2):515-518. PMID: 28673185.
      Citations: 1     Fields:    Translation:Humans
    29. Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol. 2017 10; 30(10):1378-1386. PMID: 28664940.
      Citations:    Fields:    Translation:Humans
    30. Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985. PMID: 28337527.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    31. Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol. 2017 06; 30(6):843-853. PMID: 28281554.
      Citations: 3     Fields:    Translation:HumansCells
    32. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 02; 15(2):230-269. PMID: 28188192.
      Citations: 36     Fields:    Translation:Humans
    33. Lee HC, Weber DM. Advances and practical use of monoclonal antibodies in multiple myeloma therapy. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):512-520. PMID: 27913523.
      Citations: 2     Fields:    Translation:Humans
    34. Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZ. Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. Clin Cancer Res. 2016 Oct 01; 22(19):4901-4912. PMID: 27297582.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    35. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016 05 09; 29(5):639-652. PMID: 27132469.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    36. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 04; 14(4):389-400. PMID: 27059188.
      Citations: 18     Fields:    Translation:Humans
    37. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol. 2016 Oct; 97(4):342-7. PMID: 26773409.
      Citations: 1     Fields:    Translation:Humans
    38. Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J. 2016 Feb 12; 6:e396. PMID: 26871714.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    39. Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13. PMID: 26421453.
      Citations: 7     Fields:    Translation:Humans
    40. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Jan; 16(1):36-42. PMID: 26702475.
      Citations: 1     Fields:    Translation:Humans
    41. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435. PMID: 26553768.
      Citations: 14     Fields:    Translation:Humans
    42. Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber DM, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros LJ, Young KH. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91. PMID: 26118455.
      Citations: 11     Fields:    Translation:HumansCells
    43. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74. PMID: 26104577.
      Citations: 2     Fields:    Translation:Humans
    44. Abudayyeh A, Truong LD, Beck LH, Weber DM, Rezvani K, Abdelrahim M. Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction? Clin Kidney J. 2015 Aug; 8(4):440-4. PMID: 26251713.
      Citations:    
    45. Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. Clin Cancer Res. 2015 Jun 01; 21(11):2538-45. PMID: 25748087.
      Citations: 7     Fields:    Translation:HumansCells
    46. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant. 2015 May; 50(5):668-72. PMID: 25730192.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    47. Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, Yi Q. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood. 2014 Sep 25; 124(13):2061-71. PMID: 25049282.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    48. Wuu A, Bangert SD, Weber DM, Hymes SR. Primary cutaneous plasmacytoma. Cutis. 2014 Jun; 93(6):E19-21. PMID: 24999652.
      Citations: 1     Fields:    Translation:Humans
    49. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41. PMID: 24886772.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    50. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant. 2014 Mar; 49(3):465-6. PMID: 24419515.
      Citations:    Fields:    Translation:Humans
    51. Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant. 2014 Mar; 49(3):422-5. PMID: 24317125.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    52. Cardoso RC, Gerngross PJ, Hofstede TM, Weber DM, Chambers MS. The multiple oral presentations of multiple myeloma. Support Care Cancer. 2014 Jan; 22(1):259-67. PMID: 24048519.
      Citations: 3     Fields:    Translation:Humans
    53. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013 Oct 03; 122(14):2331-7. PMID: 23950178.
      Citations: 105     Fields:    Translation:HumansCTClinical Trials
    54. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014 Feb; 28(2):373-83. PMID: 23760401.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    55. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013 Aug; 41(8):719-30. PMID: 23648290.
      Citations: 6     Fields:    Translation:HumansCells
    56. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):11-7. PMID: 23307977.
      Citations: 19     Fields:    Translation:Humans
    57. Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):319-24. PMID: 23040438.
      Citations: 18     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    58. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1211-9. PMID: 23054875.
      Citations: 8     Fields:    Translation:Humans
    59. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, Liu Z, Li H, He J, Lin P, Weber D, Davis RE, Kwak L, Cai Z, Yi Q. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013 Mar; 27(3):702-10. PMID: 22996336.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    60. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012 Oct 18; 120(16):3260-70. PMID: 22932796.
      Citations: 72     Fields:    Translation:HumansAnimalsCells
    61. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foà R, Hellmann A, Dimopoulos M, Swern AS, Knight R. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients =65 years old with relapsed or refractory multiple myeloma. Int J Hematol. 2012 Aug; 96(2):254-62. PMID: 22752567.
      Citations: 2     Fields:    Translation:Humans
    62. Alexanian R, Delasalle K, Wang M, Thomas S, Weber D. Curability of multiple myeloma. Bone Marrow Res. 2012; 2012:916479. PMID: 22675638.
      Citations:    
    63. Sweeney SA, Kumar VA, Tayar J, Weber DM, Safdar A, Alonso C, Hymes S. Case 181: synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome. Radiology. 2012 May; 263(2):613-7. PMID: 22517965.
      Citations: 4     Fields:    Translation:Humans
    64. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012 Mar 22; 119(12):2764-7. PMID: 22323483.
      Citations: 37     Fields:    Translation:Humans
    65. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6. PMID: 22231283.
      Citations: 9     Fields:    Translation:Humans
    66. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83. PMID: 21975914.
      Citations: 21     Fields:    Translation:Humans
    67. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22. PMID: 21780997.
      Citations: 25     Fields:    Translation:Humans
    68. Dimopoulos MA, Hussein M, Swern AS, Weber D. Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia. 2011 Oct; 25(10):1620-6. PMID: 21747400.
      Citations: 7     Fields:    Translation:Humans
    69. Ishak KJ, Caro JJ, Drayson MT, Dimopoulos M, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value Health. 2011 Jul-Aug; 14(5):672-8. PMID: 21839405.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    70. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011 Oct 01; 117(19):4468-74. PMID: 21437886.
      Citations: 27     Fields:    Translation:Humans
    71. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):38-43. PMID: 21273172.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    72. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011 Mar; 152(5):579-92. PMID: 21241278.
      Citations: 26     Fields:    Translation:HumansCells
    73. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene. 2011 Mar 17; 30(11):1329-40. PMID: 21057542.
      Citations: 17     Fields:    Translation:HumansCells
    74. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2445-52. PMID: 20805315.
      Citations: 24     Fields:    Translation:HumansCells
    75. Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010 Aug 15; 116(16):3807-14. PMID: 20564094.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    76. Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010 Oct; 95(10):1738-44. PMID: 20460639.
      Citations: 31     Fields:    Translation:Humans
    77. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010 Jul; 150(1):28-38. PMID: 20507313.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    78. Richards T, Weber D. Advances in treatment for relapses and refractory multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S25-42. PMID: 20213220.
      Citations: 4     Fields:    Translation:Humans
    79. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 01; 28(1):132-5. PMID: 19901114.
      Citations: 17     Fields:    Translation:Humans
    80. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer J. 2009 Nov-Dec; 15(6):485-93. PMID: 20010168.
      Citations: 1     Fields:    Translation:Humans
    81. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):908-42. PMID: 19878637.
      Citations: 43     Fields:    Translation:Humans
    82. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov; 23(11):2147-52. PMID: 19626046.
      Citations: 93     Fields:    Translation:Humans
    83. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jul; 15(7):812-6. PMID: 19539212.
      Citations: 13     Fields:    Translation:HumansAnimalsCTClinical Trials
    84. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23. PMID: 19450756.
      Citations: 34     Fields:    Translation:Humans
    85. Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, Dimopoulos MA. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009 Jun; 82(6):426-32. PMID: 19302559.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    86. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008 Dec; 14(12):1401-7. PMID: 19041063.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    87. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008 Dec 01; 112(12):4445-51. PMID: 18799726.
      Citations: 49     Fields:    Translation:Humans
    88. Campagnaro E, Saliba R, Giralt S, Roden L, Mendoza F, Aleman A, Cleeland C, Weber D, Brown J, Anderson KO. Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer. 2008 Apr 01; 112(7):1617-24. PMID: 18260091.
      Citations: 10     Fields:    Translation:Humans
    89. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb; 22(2):414-23. PMID: 18094721.
      Citations: 147     Fields:    Translation:Humans
    90. Thomas SK, Richards TA, Weber DM. Lenalidomide in multiple myeloma. Best Pract Res Clin Haematol. 2007 Dec; 20(4):717-35. PMID: 18070715.
      Citations: 1     Fields:    Translation:Humans
    91. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22; 357(21):2133-42. PMID: 18032763.
      Citations: 316     Fields:    Translation:HumansCTClinical Trials
    92. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb; 22(2):231-9. PMID: 17972944.
      Citations: 70     Fields:    Translation:Humans
    93. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1066-72. PMID: 17697969.
      Citations: 10     Fields:    Translation:HumansCells
    94. Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R, Breitz H, Alexanian R, Champlin R, Giralt S. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant. 2007 May; 13(5):543-9. PMID: 17448913.
      Citations: 5     Fields:    Translation:Humans
    95. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):118-47. PMID: 17335683.
      Citations: 16     Fields:    Translation:Humans
    96. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007 Mar; 39(5):279-83. PMID: 17262062.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    97. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma. 2006 Jul; 47(7):1360-4. PMID: 16923569.
      Citations: 3     Fields:    Translation:Humans
    98. Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation. Mod Pathol. 2006 Jul; 19(7):891-8. PMID: 16636680.
      Citations: 3     Fields:    Translation:HumansCells
    99. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, Duvic M. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006 Jan 15; 107(2):463-6. PMID: 16179379.
      Citations: 10     Fields:    Translation:Humans
    100. Moulopoulos LA, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R, Dimopoulos MA. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol. 2005 Nov; 16(11):1824-8. PMID: 16087694.
      Citations: 23     Fields:    Translation:Humans
    101. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer. 2005 Jul 11; 93(1):70-80. PMID: 15970928.
      Citations: 25     Fields:    Translation:HumansCells
    102. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol. 2005 Jul; 79(3):194-7. PMID: 15981221.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    103. Weber DM. Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program. 2005; 373-6. PMID: 16304406.
      Citations: 43     Fields:    Translation:Humans
    104. Dimopoulos MA, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, Kyrtsonis MC, Anagnostopoulos N, Pangalis GA, Weber DM. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma. 2004 Oct; 45(10):2057-61. PMID: 15370250.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    105. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant. 2004 Aug; 34(3):229-34. PMID: 15170166.
      Citations: 9     Fields:    Translation:Humans
    106. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004 Jun 15; 100(12):2607-12. PMID: 15197803.
      Citations: 16     Fields:    Translation:Humans
    107. Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, de Lima M, Anagnostopoulos A, Giralt S. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma. 2004 Apr; 45(4):755-9. PMID: 15160952.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    108. Anagnostopoulos A, Aleman A, Yang Y, Donato M, Weber D, Champlin R, Smith T, Alexanian R, Giralt S. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant. 2004 Mar; 33(6):623-8. PMID: 14730336.
      Citations: 1     Fields:    Translation:Humans
    109. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004 Apr 15; 103(8):3175-84. PMID: 15070700.
      Citations: 103     Fields:    Translation:HumansCells
    110. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003 Dec 01; 21(23):4444-54. PMID: 14645435.
      Citations: 15     Fields:    Translation:Humans
    111. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol. 2003 Oct; 40(4 Suppl 4):3-7. PMID: 15015890.
      Citations: 3     Fields:    Translation:Humans
    112. Ahmed M, Giles F, Joe Y, Weber DM, Jilani I, Manshouri T, Giralt S, De Lima M, Keating M, Albitar M. Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma. Eur J Haematol. 2003 Sep; 71(3):174-8. PMID: 12930317.
      Citations: 3     Fields:    Translation:HumansCells
    113. Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control. 2003 Sep-Oct; 10(5):375-83. PMID: 14581892.
      Citations: 5     Fields:    Translation:Humans
    114. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003 Jun; 121(5):768-71. PMID: 12780791.
      Citations: 24     Fields:    Translation:Humans
    115. Weber DM. Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston Park). 2003 Jun; 17(6):765-7. PMID: 12846120.
      Citations:    Fields:    Translation:Humans
    116. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun; 121(5):749-57. PMID: 12780789.
      Citations: 546     Fields:    Translation:Humans
    117. Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, Alexanian R, Weber D, Maloney D, Holmberg L, Rajandran J, Breitz H, Ghalie R, Champlin R. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood. 2003 Oct 01; 102(7):2684-91. PMID: 12730103.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    118. Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):206-10. PMID: 12720137.
      Citations: 6     Fields:    Translation:Humans
    119. Weber D, Treon SP, Emmanouilides C, Branagan AR, Byrd JC, Bladé J, Kimby E. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):127-31. PMID: 12720121.
      Citations: 10     Fields:    Translation:Humans
    120. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):243-7. PMID: 12720145.
      Citations: 14     Fields:    Translation:Humans
    121. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003 Jan 01; 21(1):16-9. PMID: 12506164.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    122. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002 Sep; 30(6):367-73. PMID: 12235521.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    123. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol. 2002 Jul; 13(7):1116-9. PMID: 12176792.
      Citations: 7     Fields:    Translation:Humans
    124. Weber DM. Newly diagnosed multiple myeloma. Curr Treat Options Oncol. 2002 Jun; 3(3):235-45. PMID: 12057069.
      Citations: 1     Fields:    Translation:Humans
    125. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002 Mar 01; 94(5):1532-7. PMID: 11920511.
      Citations: 21     Fields:    Translation:Humans
    126. Alexanian R, Weber D. Recent advances in treatment of multiple myeloma and Waldenström's macroglobulinemia. Biomed Pharmacother. 2001 Nov; 55(9-10):550-2. PMID: 11769965.
      Citations:    Fields:    Translation:Humans
    127. Mansoor A, Medeiros LJ, Weber DM, Alexanian R, Hayes K, Jones D, Lai R, Glassman A, Bueso-Ramos CE. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001 Oct; 116(4):543-9. PMID: 11601139.
      Citations: 10     Fields:    Translation:HumansCells
    128. Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R, Giralt S. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant. 2001 May; 27(10):1027-9. PMID: 11438816.
      Citations: 4     Fields:    Translation:Humans
    129. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, Champlin R. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001 May; 27(10):1037-43. PMID: 11438818.
      Citations: 20     Fields:    Translation:Humans
    130. Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001 Apr; 27(8):821-8. PMID: 11477439.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    131. Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2001 Mar; 10(3):249-59. PMID: 11303595.
      Citations: 11     Fields:    Translation:HumansCells
    132. Younes A, Cristofanilli M, McLaughlin P, Hagemeister FB, Weber D, Mesina O, Cabanillas F. Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma. Leuk Lymphoma. 2000 Dec; 40(1-2):79-85. PMID: 11426631.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    133. Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol. 2000 Nov; 65(3):204-9. PMID: 11074536.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    134. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999 Sep; 52(3):245-9. PMID: 10580871.
      Citations: 46     Fields:    Translation:HumansCells
    135. Siddique I, Papadakis KA, Weber DM, Glober G. Recurrent bleeding from a duodenal plasmacytoma treated successfully with embolization of the gastroduodenal artery. Am J Gastroenterol. 1999 Jun; 94(6):1691-2. PMID: 10364048.
      Citations: 2     Fields:    Translation:Humans
    136. Mathews VP, Caldemeyer KS, Lowe MJ, Greenspan SL, Weber DM, Ulmer JL. Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology. 1999 Apr; 211(1):257-63. PMID: 10189481.
      Citations: 40     Fields:    Translation:Humans
    137. Alexanian R, Weber D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med. 1999 Feb; 123(2):108-13. PMID: 10050782.
      Citations: 5     Fields:    Translation:Humans
    138. Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma. 1998 Dec; 32(1-2):97-106. PMID: 10037005.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    139. NCCN practice guidelines for multiple myeloma. National Comprehensive Cancer Network. Oncology (Williston Park). 1998 Nov; 12(11A):317-51. PMID: 10028515.
      Citations:    Fields:    Translation:Humans
    140. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998 Jul 15; 41(5):1063-7. PMID: 9719116.
      Citations: 28     Fields:    Translation:Humans
    141. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998 Apr; 101(1):189-94. PMID: 9576200.
      Citations: 10     Fields:    Translation:HumansCells
    142. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol. 1997 Jun; 97(4):810-4. PMID: 9217181.
      Citations: 21     Fields:    Translation:Humans
    143. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73. PMID: 9053492.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    144. Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996 Jun; 52(2):77-81. PMID: 8638645.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    145. Alexanian R, Weber D. Whither interferon for myeloma and other hematologic malignancies? Ann Intern Med. 1996 Jan 15; 124(2):264-5. PMID: 8534004.
      Citations: 2     Fields:    Translation:Humans
    146. Daliani D, Weber D, Alexanian R. Light-heavy chain deposition disease progressing to multiple myeloma. Am J Hematol. 1995 Dec; 50(4):296-8. PMID: 7485106.
      Citations: 3     Fields:    Translation:Humans
    147. Telen MJ. Clinical problem-solving: costly errors. N Engl J Med. 1995 Oct 19; 333(16):1080-1. PMID: 7675064.
      Citations:    Fields:    Translation:Humans
    148. Weber DM, Daliani D, Alexanian R. Clinical problem-solving: costly errors. N Engl J Med. 1995 Oct 19; 333(16):1080; author reply 1081. PMID: 7675063.
      Citations:    Fields:    Translation:Humans
    149. Melnyk A, Graham NJ, Weber D, Walsh GL. Lethal tracheal dissolution during treatment for thyroid lymphoma. Thorax. 1995 Oct; 50(10):1120-1. PMID: 7491567.
      Citations:    Fields:    Translation:Humans
    150. Vernon SW, Yeomans AC, Frankowski R, Weber D, Vogel VG. Behavioral and social factors that predict participation in the Breast Cancer Prevention Trial. Ann N Y Acad Sci. 1995 Sep 30; 768:300. PMID: 8526373.
      Citations:    Fields:    Translation:Humans
    151. Weber D, Dimopoulos M, Sinicrope F, Alexanian R. VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1995 Sep; 19(1-2):159-63. PMID: 8574163.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    152. Yeomans-Kinney A, Vernon SW, Frankowski RF, Weber DM, Bitsura JM, Vogel VG. Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer. 1995 Jul 01; 76(1):46-56. PMID: 8630876.
      Citations: 11     Fields:    Translation:Humans
    153. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol. 1995 Jan; 6(1):49-52. PMID: 7710983.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    154. Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI, Alexanian R. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 1995 Jan; 13(1):251-6. PMID: 7799027.
      Citations: 38     Fields:    Translation:Humans
    155. Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994 Dec; 12(12):2694-8. PMID: 7989946.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    156. Weber DM, Dimopoulos MA, Anandu DP, Pugh WC, Steinbach G. Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology. 1994 Dec; 107(6):1835-8. PMID: 7958698.
      Citations: 18     Fields:    Translation:HumansCells
    157. Dimopoulos MA, Arbuck S, Huber M, Weber D, Luckett R, Delasalle K, Alexanian R. Primary therapy of multiple myeloma with paclitaxel (taxol). Ann Oncol. 1994 Oct; 5(8):757-9. PMID: 7826909.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    158. Dimopoulos MA, Weber DM, Hester J, Delasalle K, Champlin R, Alexanian R. Intensive sequential therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1994 May; 13(5-6):479-84. PMID: 7915163.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    159. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. Ann Oncol. 1994 Mar; 5(3):288-9. PMID: 7514439.
      Citations: 5     Fields:    Translation:Humans
    160. Swan JS, Grist TM, Weber DM, Sproat IA, Wojtowycz MM. MR angiography of the pelvis with variable velocity encoding and a phased-array coil. Radiology. 1994 Feb; 190(2):363-9. PMID: 8284382.
      Citations: 1     Fields:    Translation:Humans
    161. Korosec FR, Grist TM, Polzin JA, Weber DM, Mistretta CA. MR angiography using velocity-selective preparation pulses and segmented gradient-echo acquisition. Magn Reson Med. 1993 Dec; 30(6):704-14. PMID: 8139452.
      Citations: 6     Fields:    Translation:Humans
    162. Wang Y, Weber DM, Korosec FR, Mistretta CA, Grist TM, Swan JS, Turski PA. Generalized matched filtering for time-resolved MR angiography of pulsatile flow. Magn Reson Med. 1993 Nov; 30(5):600-8. PMID: 8259060.
      Citations: 1     Fields:    Translation:Humans
    163. Dimopoulos MA, Weber D, Delasalle KB, Alexanian R. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer. 1993 Nov 01; 72(9):2589-92. PMID: 8402480.
      Citations: 2     Fields:    Translation:Humans
    164. Dimopoulos MA, Weber DM, Estey EE, Alexanian R. Primary treatment with 2-chlorodeoxyadenosine of low grade lymphomas that produce IgG or IgA immunoglobulin. Am J Hematol. 1993 Aug; 43(4):326-7. PMID: 8103966.
      Citations:    Fields:    Translation:Humans
    165. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993 Jul; 11(7):1311-5. PMID: 8315427.
      Citations: 31     Fields:    Translation:Humans
    166. Swan JS, Heiner JP, Rao VK, Weber DM. Preoperative evaluation of giant cell tumors of the radius with magnetic resonance angiography. J Hand Surg Am. 1993 May; 18(3):499-503. PMID: 8515023.
      Citations: 1     Fields:    Translation:Humans
    167. Swan JS, Weber DM, Korosec FR, Grist TM, Heiner JP. Combined MRI and MRA for limb salvage planning. J Comput Assist Tomogr. 1993 Mar-Apr; 17(2):339-42. PMID: 8454767.
      Citations:    Fields:    Translation:Humans
    168. Weber DM, Dimopoulos MA, Alexanian R. Increased neurotoxicity with VAD-cyclosporin in multiple myeloma. Lancet. 1993 Feb 27; 341(8844):558-9. PMID: 8094795.
      Citations: 1     Fields:    Translation:Humans
    169. Weber DM, Wang Y, Korosec FR, Mistretta CA. Quantitative velocity images from thick slab 2D phase contrast. Magn Reson Med. 1993 Feb; 29(2):216-25. PMID: 8429786.
      Citations:    Fields:    Translation:Humans
    170. Swan JS, Weber DM, Grist TM, Wojtowycz MM, Korosec FR, Mistretta CA. Peripheral MR angiography with variable velocity encoding. Work in progress. Radiology. 1992 Sep; 184(3):813-7. PMID: 1509072.
      Citations: 2     Fields:    Translation:Humans
    171. Korosec FR, Weber DM, Mistretta CA, Turski PA, Bernstein MA. A data adaptive reprojection technique for MR angiography. Magn Reson Med. 1992 Apr; 24(2):262-74. PMID: 1569866.
      Citations: 1     Fields:    Translation:Humans
    172. NCCN guidelines® insights multiple myeloma, version 3.2016 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network. 14:389-400.
    173. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer Journal. 4.
    174. Catheter-associated left-sided valvular endocarditis due to Corynebacterium striatum. Cancer Bulletin. 45:460-464.
    175. Lymphoplasmacytic lymphoma/waldenstrom's macroglobulinemia-βone marrow morphology identifies a subset of patients with accelerated clinical course. Blood. 96.
    176. The multiple oral presentations of multiple myeloma. Supportive Care in Cancer. 22:259-267.
    177. Thalidombde with dexamethasone for resistant multiple myeloma. Blood. 96.
    178. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Journal of Hematology and Oncology. 8.
    179. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (mm). Blood. 96.
    180. Membranous nephropathy in autologous hematopoietic stem cell transplant. CKJ: Clinical Kidney Journal. 8:440-444.
    181. Myeloma and leukemia. 509-529.
    182. Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expression. Clinical Cancer Research. 22:4901-4912.
    183. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell.
    184. Abnormal serum protein electrophoresis. Unknown Journal. 264-267.
    185. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia.
    186. Crystal-storing histiocytosis. Histopathology. 68:482-491.
    187. Thalidomide for resistant and relapsing myeloma. Seminars in Hematology. 37:22-25.
    188. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leukemia and Lymphoma. 1-10.
    189. Prognostic features of asymptomatic multiple myeloma. Cancer Research Therapy and Control. 6:113.
    190. Targeting the spleen tyrosine kinase with fostamatinib as a strategy against Waldenström Macroglobulinemia. Clinical Cancer Research. 21:2538-2545.
    191. American Society of Hematology 49th Annual Meeting. P and T. 33:111.
    192. Multiple myeloma, version 2.2016. JNCCN Journal of the National Comprehensive Cancer Network. 13:1398-1435.
    193. Magnetic resonance imaging of the bone marrow in plasma cell dyscrasias. Cancer Research Therapy and Control. 6:91-92.
    194. Reply. Gastroenterology. 109:334-335.
    195. Case 181. Radiology. 262:361-363.
    196. Filgrastim alone versus chemotherapy plis filgrastim for peripheral blood stem cell mobilization in multiple myeloma. Blood. 96.
    197. Multiple myeloma. 263-269.
    WEBER's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (532)
    Explore
    _
    Co-Authors (99)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _